Physician profile
Larry Gibson
NPI 1114013521
$16,788.90
in general payments reported to CMS, 2019-2025
64 companies · $2,424 in 2025
The $2,424 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,081 · 2020: $1,635 · 2021: $2,713 · 2022: $2,864 · 2023: $2,533 · 2024: $2,539 · 2025: $2,424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,495.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,327.38 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $1,284.09 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Teva Pharmaceuticals USA, INC. | $1,064.40 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $975.82 | 2021-2025 | |
| Ucb, INC. | $797.92 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Acadia Pharmaceuticals INC | $795.70 | 2019-2025 | Nuplazid |
| Lundbeck LLC | $738.76 | 2020-2025 | Vyepti, Rexulti |
| Eisai INC. | $601.19 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $567.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $535.54 | 2019-2025 | |
| Celgene Corporation | $533.04 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $507.80 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Neurelis, INC. | $507.25 | 2020-2025 | Valtoco |
| Emd Serono, INC. | $492.52 | 2019-2025 | Mavenclad |
| Amgen INC. | $444.77 | 2019-2025 | Uplizna, Aimovig |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.